阿尔茨海默病试验正转向受癌症研究启发的多靶点方法，即便Novo Nordisk的司美格鲁肽试验失败。只有两种药物——Eli Lilly的Kisunla和Eisai与Biogen的Leqembi——被广泛批准用于减缓疾病进展。这种演变将这种脑部退化疾病视为复杂系统，在其全球影响下寻求新的遏止途径。
阿尔茨海默病导致全球超过5500万痴呆病例中的约60%，其特征是大脑中淀粉样蛋白和tau蛋白积聚。
目前仅有两种药物被广泛批准用于减缓其进展：Eli Lilly的Kisunla和Eisai与Biogen的Leqembi。这两种药物通过清除有毒的淀粉样蛋白斑块，将进展速度降低约30%。
专家们强调试验中的关键转变，例如Novo Nordisk的重磅GLP-1药物司美格鲁肽用于阿尔茨海默病的试验失败。这些努力凸显了将这种脑部退化疾病视为复杂通路网络的观点，类似于癌症治疗领域的近期变革。
借鉴癌症的多靶点策略，研究人员正在推进工作，以识别更多靶点和方法，更全面地阻断该疾病。
A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.
由 AI 报道
A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.